BioSante Pharmaceuticals has presented H1N1 vaccine results at the Immunotherapeutics & Vaccine Summit in Providence, RI. BioSante claims that its vaccine adjuvant – BioVant has increased the protective effect of vaccines for multiple flu strains, which resulted in 100% protection from symptoms of illness, including weight loss, and death in animal studies.
The BioSante presentation, BioVant Calcium Phosphate (CaP) Nanoparticles: An Effective & Safe Adjuvant for Influenza Vaccines including H1N1 and H5N1, showed that BioVant-adjuvant effectively enhanced the natural immune response to the swine flu, using a BioVant-adjuvanted matrix protein M1 vaccine, and to H5N1 (bird flu), using a BioVant-adjuvanted H5N1 vaccine delivered via intranasal administration.
Michael Snabes, vice president of clinical development at BioSante, said: “The results of the BioVant-influenza studies suggest that BioVant can increase the efficacy of a potential adjuvant-enhanced H1N1 vaccine. The exciting prospect is that BioVant also may allow use of lower doses of H1N1 swine flu vaccines in order to stretch potentially limited vaccine supplies.”